Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Soiken Holdings's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Soiken Holdings was 0.01. The lowest was 0.01. And the median was 0.01.
TSE:2385's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Soiken Holdings Debt-to-Equity Related Terms
Soiken Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Soiken Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2385 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Soiken Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soiken Holdings Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soiken Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Soiken Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soiken Holdings (TSE:2385) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Soiken Holdings and its competitors. Over the past decade, Soiken Holdings' Debt-to-Equity has ranged from 0.01 to 0.01. According to the industry distribution chart, Soiken Holdings ranks #999999 out of 954 companies in the Biotechnology industry.
Is Soiken Holdings' Debt-to-Equity too high?
Soiken Holdings' current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.01. Based on the distribution chart, Soiken Holdings ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Soiken Holdings has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soiken Holdings' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Soiken Holdings ranks #999999 out of 954 companies for Debt-to-Equity. This places Soiken Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Historically, Soiken Holdings' own Debt-to-Equity has ranged from 0.01 to 0.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Soiken Holdings and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Soiken Holdings's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soiken Holdings stock overvalued right now?
Based on GuruFocus' analysis, Soiken Holdings (TSE:2385) is currently considered Significantly Overvalued. The stock's GF Value™ is 円112.05, compared to a current price of 円220.00 — trading 96.3% above its estimated fair value. The current Debt-to-Equity is 0.00. Soiken Holdings' overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Soiken Holdings (TSE:2385), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Soiken Holdings (TSE:2385) Overvalued in 2026?
Based on GuruFocus' analysis, Soiken Holdings stock appears to be overvalued.
The current stock price of 円220.00 is trading 96.3% above its estimated GF Value™ of 円112.05.
GuruFocus considers Soiken Holdings to be Significantly Overvalued.
Key valuation signals for TSE:2385:
Debt-to-Equity: 0.00
GF Value™: 円112.05 vs. price of 円220.00 (96.3% above fair value)
No single metric tells the full story. See the TSE:2385 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Soiken Holdings Inc operates as a biotechnology company in Japan. It provides clinical testing for pharmaceutical and food manufacturers that develop drugs and health food products based on biomarkers. It is involved in the marketing research and post-marketing surveillance of health supplements.
58GF Score
Get the complete analysis for TSE:2385
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2385 has been successfully added to your 
